Abstract: Provided herein are peptides selective for combinations of Mcl-1/Bfl-1/Bcl-xL. Also provided are compositions containing these polypeptides and methods of using such peptides in the treatment of cancer that include administering to a subject one of the polypeptides.
Type:
Grant
Filed:
September 17, 2019
Date of Patent:
March 29, 2022
Assignees:
Massachusetts Institute of Technology, Trustees of Darthmouth College
Inventors:
Vincent Xue, Justin Michael Jenson, Amy E. Keating, Jianfu Zhou, Gevorg Grigoryan
Abstract: Methods of suppressing a humoral immune response to a thymus-dependent (TD) antigen are disclosed. The methods involve administering to a subject a TD antigen with an antagonist of a molecule which mediates contact-dependent helper effector functions. In a preferred embodiment, the antagonist is an antagonist of gp39. Primary and secondary humoral immune responses can be suppressed and suppression is prolonged.